Aprea Therapeutics
Price & Volume
Stats
See more52W Range | $1.37-$5.01 |
Market Cap | $8.3M |
Shares Short | 85,074 |
Financials
See moreRevenue (12 Mos) | $841,012 |
Revenue Growth (YoY) | -79% |
Gross Profit (12 Mos) | -$8.7M |
Diluted EPS | -$2.30 |
News
See moreYahoo Finance • last month
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
Yahoo Finance • 4 months ago
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
Yahoo Finance • 5 months ago
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
Yahoo Finance • 7 months ago
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
About
CEO | Dr. Oren Gilad Ph.D. |
CFO | Mr. John P. Hamill CPA |
Address | 3805 Old Easton Road, Doylestown, PA, United States, 18902 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 8 |
